Key result
AMoPac monitoring is rated useful by 100% of GPs for assessing hypertension medication adherence.
Why the study?
Non-adherence to antihypertensive agents is common and general practitioners cannot reliably predict adherence, making adherence knowledge clinically valuable in patients not responding to treatment.
Does the Adherence Monitoring Package (AMoPac) improve the identification of medication non-adherence by general practitioners in patients with hypertension suspected of non-response?
Observational (n=15)
Does the Adherence Monitoring Package (AMoPac) improve the identification of medication non-adherence by general practitioners in patients with hypertension suspected of non-response?
Integrating an adherence monitoring package into routine general practice successfully aids in identifying or excluding non-adherence as a cause of treatment failure in hypertension.
AMoPac may aid GPs in excluding non-adherence; hypothesis-generating and requires randomized validation before adoption.
BACKGROUND: Non-adherence to antihypertensive agents is common, mainly because of the low perceived burden of high blood pressure. General practitioners (GPs) are unable to predict whether patients are adhering to a recommended treatment. Knowledge about adherence might be of clinical interest in patients non-responding to antihypertensive treatment. AIM: To assess the usefulness of an Adherence Monitoring Package (AMoPac) to identify non-adherence in patients non-responding to antihypertensive treatment. METHODS: ertensive patients') is an observational study among GPs and ambulatory patients with hypertension in a real-world setting. The primary outcome was GPs' perceived usefulness of AMoPac. Secondary outcomes were (1) frequency of medication problems and prescribing errors; (2) types of pharmacist's' recommendations; (3) acceptance of the recommendations by GPs; (4) medication adherence and (5) patients' satisfaction. Outcomes are reported descriptively. Data were collected with questionnaires and electronic monitoring of medicine intake. RESULTS: Fifteen GPs and 15 patients with hypertension participated in the AMoPac-HYP Study. Patients were on average 62 years old, and mean blood pressure was 137/83 mmHg. All GPs rated AMoPac as useful. The most frequently mentioned use was excluding non-adherence in patients with hypertension (93%). Medication problems and prescribing errors were observed in 80% of the patients. The study pharmacist recommended adherence support (N=9 patients) and treatment optimisation (N=8 patients). The recommendations were accepted and implemented in 10 of 17 cases by the GP. Patients' mean taking and timing adherence were 90% and 86%, respectively. Satisfaction with the study procedures among patients was high. CONCLUSION: AMoPac was rated as useful for identifying and excluding non-adherence in patients with hypertension and was highly accepted among patients. Including adherence data in clinical decision-making could contribute to optimising patient care.
No takes yet. Share an insight, caveat, or question.
Dietrich et al. (2024) conducted an observational in Hypertension with suspected non-response to treatment (n=15). Adherence Monitoring Package (AMoPac) was evaluated on GPs' perceived usefulness of AMoPac. The Adherence Monitoring Package (AMoPac) was rated as useful by 100% of participating GPs for assessing and excluding medication non-adherence in hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: